Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared a recent article by him and colleagues on X:

“IO has changed tetrodotoxin and outcome in advanced lung cancer. It’s time that academic trials (PULSE by Benjamin Besse) and international grants test IO de-escalation to ensure patients receive these drugs, increasing outcomes for more patients worldwide while decreasing financial toxicity.

Thanks to all the authors.”

“De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?“

Authors: Jordi Remon, Martina Bortolot, Paolo Bironzo, Francesco Cortiula, Jessica Menis, Mariana Brandao, Jarushka Naidoo, Robin van Geel, Noemi Reguart, Oscar Arrieta, Giannis Mountzios, Lizza E L Hendriks and Benjamin Besse

Jordi Remon-De-Escalation

Jordi Remon: De-Escalation strategies with immune checkpoint blockers in NSCLC